Literature DB >> 9930931

Transplantation of human fetal pancreas: fresh vs. cultured fetal islets or ICCS.

G M Beattie1, A D Lopez, T Otonkoski, A Hayek.   

Abstract

The paucity of human adult islets available for transplantation in IDDM makes the use of human fetal pancreas a potential alternative. Fetal pancreatic endocrine cells grow and differentiate over time when fresh explants or cultured islet-like cell clusters (ICCs) are transplanted under the kidney capsule in athymic nude mice. We have recently developed a procedure to isolate fetal islets, which differ from ICCs in their beta-cell content. This study was undertaken to compare the maturation and growth of grafts from purified fetal islets, containing mostly beta-cells, to grafts of mostly undifferentiated endocrine cell precursors, cultured as ICCs, and fresh, uncultured tissue. Total insulin content was highest in the fresh tissue pre-transplant while insulin levels fell precipitously during culture as either fetal islets or ICCs. Although 500 fetal islets contained more insulin than 500 ICCS before transplantation, the insulin content of the resulting grafts was the same 3 months post-transplantation. The degree of stimulation following glucose challenge was comparable, as was the histological appearance. However 70 mg of fresh tissue was needed to generate the fetal islets while only 30 mg was needed for the ICCs. Grafts of 30 mg fresh tissue also had similar total insulin contents and stimulation following glucose challenge, but, when normalized to DNA there was a significantly higher concentration of insulin in the grafts from ICCs or fetal islets. Moreover there were distinct morphological differences, with fibrous and ductal elements prominent in the grafts from fresh tissue, which were also much larger and more diffuse, with cystic elements evident macroscopically. Quantitative immunohistochemical analysis showed that grafts from cultured tissue were 48.3+/-5% positive for immunoreactive insulin compared with grafts from fresh tissue which were only 13.3+/-1.4% positive for insulin. In conclusion cultured ICCs, a heterogeneous mixture of hormone-containing and undifferentiated endocrine cells, are a preferable source for transplantation than either purified fetal islets or uncultured tissue.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9930931     DOI: 10.1007/s001090050304

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  6 in total

Review 1.  Alternatives to unmodified human islets for transplantation.

Authors:  Alberto Hayek; Gillian M Beattie
Journal:  Curr Diab Rep       Date:  2002-08       Impact factor: 4.810

2.  Global gene expression profiling and histochemical analysis of the developing human fetal pancreas.

Authors:  S A Sarkar; S Kobberup; R Wong; A D Lopez; N Quayum; T Still; A Kutchma; J N Jensen; R Gianani; G M Beattie; J Jensen; A Hayek; J C Hutton
Journal:  Diabetologia       Date:  2007-12-18       Impact factor: 10.122

3.  Transplantation of insulin-producing cells from umbilical cord mesenchymal stem cells for the treatment of streptozotocin-induced diabetic rats.

Authors:  Pei-Jiun Tsai; Hwai-Shi Wang; Yi-Ming Shyr; Zen-Chung Weng; Ling-Chen Tai; Jia-Fwu Shyu; Tien-Hua Chen
Journal:  J Biomed Sci       Date:  2012-04-30       Impact factor: 8.410

4.  Endothelium-derived Netrin-4 supports pancreatic epithelial cell adhesion and differentiation through integrins α2β1 and α3β1.

Authors:  Mayra Yebra; Giuseppe R Diaferia; Anthony M P Montgomery; Thomas Kaido; William J Brunken; Manuel Koch; Gary Hardiman; Laura Crisa; Vincenzo Cirulli
Journal:  PLoS One       Date:  2011-07-29       Impact factor: 3.240

Review 5.  Brief review: cell replacement therapies to treat type 1 diabetes mellitus.

Authors:  Alberto Hayek; Charles C King
Journal:  Clin Diabetes Endocrinol       Date:  2016-02-25

6.  Isolation, culture, and imaging of human fetal pancreatic cell clusters.

Authors:  Ana D Lopez; Ayse G Kayali; Alberto Hayek; Charles C King
Journal:  J Vis Exp       Date:  2014-05-18       Impact factor: 1.355

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.